MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on August 6, 2008; DOI: 10.1124/mol.108.046979


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.046979v1
74/5/1417    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Sato, M.
Right arrow Articles by Summers, R. J.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sato, M.
Right arrow Articles by Summers, R. J.


Received for publication March 18, 2008.
Revised August 3, 2008.
Accepted for publication August 6, 2008.

The {beta}3-adrenoceptor agonist L755507 and antagonist L748337 activate different signalling pathways in CHO-K1 cells stably expressing the human {beta}3-adrenoceptor

Masaaki Sato 1, Dana S Hutchinson 1, Bronwyn A Evans 1, Roger J. Summers 1*

1 Monash University

* Address correspondence to: E-mail: roger.summers{at}med.monash.edu.au

Abstract

This study identifies signaling pathways activated by the {beta}2-/{beta}3-AR agonist zinterol, the selective {beta}3-AR agonist L755507 and the selective {beta}3-AR antagonist L748337 in CHO-K1 cells expressing human {beta}3-adrenoceptors. Zinterol and L755507 caused a robust concentration-dependent increase in cAMP accumulation (pEC50 8.5 and 12.3 respectively), while L748337 had low efficacy. Maximal cAMP accumulation with zinterol and L755507 was increased after pre-treatment with pertussis toxin, indicating that the human {beta}3-AR couples to Gi as well as Gs. In contrast to cAMP, zinterol, L755507 and L748337 increased phosphorylation of Erk1/2 with very high potency (pEC50 10.9, 11.7 and 11.6). These compounds also stimulated phosphorylation of p38 MAPK, but with much lower potency than Erk1/2 (pEC50 5.9, 5.5 and 5.7 respectively). Pertussis toxin completely blocked Erk1/2 and p38 MAPK phosphorylation in response to L748337, demonstrating a requirement for Gi/o coupling, whereas L755507-stimulated p38 MAPK phosphorylation was not inhibited by pertussis toxin, and Erk1/2 phosphorylation was inhibited by only 30%. We found that high levels of cAMP interfered with agonist-activated p38 MAPK phosphorylation. L748337 increased extracellular acidification rate (ECAR) in the cytosensor microphysiometer with efficacy similar to zinterol and L755507, albeit with lower potency (pEC50 7.2 compared to zinterol, 8.1, and L755507, 8.6). The ECAR response to L748337 was largely via activation of p38 MAPK, demonstrated by 65% inhibition with RWJ67657. We conclude that the {beta}3-AR agonist L755507 couples to both Gs and Gi to activate adenylate cyclase and MAPK signaling, whereas the {beta}3-AR antagonist L748337 couples predominantly to Gi to activate MAPK signaling.


Key words: Adrenergic, Gi family, Gs family, cAMP, MAP Kinase





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics